A comparison of the effects of Penicillamine, Trientine, and trithiomolybdate on [35S]-labeled metallothionein in vitro; implications for Wilson's disease therapy
- 1 February 1991
- journal article
- research article
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 41 (2) , 87-92
- https://doi.org/10.1016/0162-0134(91)80002-y
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- WILSON'S DISEASE PATIENTS CAN BE DECOPPEREDThe Lancet, 1989
- Profiles of 67Cu in blood, bile, urine and faeces from 67Cu-primed lambs: effect of 99Mo-labelled tetrathiomolybdate on the metabolism of recently stored tissue 67CuBritish Journal of Nutrition, 1989
- Studies on the uptake and subsequent tissue distribution of [35S]trithiomolybdate in rats: effects on metallothionein copper in liver, kidney, andJournal of Inorganic Biochemistry, 1988
- Studies of the changes in systemic copper metabolism and excretion produced by the intravenous administration of trithiomolybdate in sheepBritish Journal of Nutrition, 1988
- The uptake and intracellular distribution of [35S] trithiomolybdate in bovine liver in vivoJournal of Inorganic Biochemistry, 1987
- The Use of Trientine in Preventing the Effects of Interrupting Penicillamine Therapy in Wilson's DiseaseNew England Journal of Medicine, 1987
- PENICILLAMINE MAY DETOXIFY COPPER IN WILSON'S DISEASEThe Lancet, 1987
- Free radical problems of the newbornProceedings of the Nutrition Society, 1987
- D-penicillamine induces rat hepatic metallothioneinToxicology, 1986
- Copper: Its Role in the Pathogenesis of Liver DiseaseSeminars in Liver Disease, 1984